הכנסה תפעולית לפני ניכוי פחת: Creative Medical Technology (CELZ)

Creative Medical Technology (CELZ) operates within a narrow regeneration segment where success depends on new patents. The EBITDA timeline visualizes profit dynamics, with 0.00 representing the most recent level. The company is developing cell therapy for orthopedics and sexual pathologies to replace surgical interventions. Unique proprietary treatment protocols for urological issues using the patient's own cells provide high pricing power.

Creative Medical Technology focuses on the development of cell therapy, where investments in clinical trials currently serve as the primary source of liquidity. By analyzing EBITDA cash flow, an investor can see the actual volume of operating cash inflows before non-cash expenses, allowing for the real-time assessment of systemic funding failures and the resilience of the business model to macroeconomic shocks.